Meta-Analysis of Glioblastoma Combination Therapies with Tyrosine Kinase Inhibitors

10 randomized controlled trials with 1,435 glioblastoma patients were analyzed in this meta-analysis. The study, authored by Pan Wei and updated in April 2026, synthesizes evidence on the efficacy and safety of tyrosine kinase inhibitor combination therapies.

Use Cases

• Evaluating progression-free survival (PFS) and overall survival (OS) outcomes based on hazard ratios from the meta-analysis.
• Assessing treatment safety profiles based on adverse event (AE) incidence rates detailed in the results.
• Comparing objective response rates (ORR) between combination and control regimens using the pooled risk ratios.
• Conducting subgroup analyses on treatment efficacy stratified by combination regimen or glioblastoma status as described in the methods.

Strengths

• Includes data from 10 randomized controlled trials, a standard for clinical evidence.
• Applies trial sequential analysis to control for false-positive and false-negative conclusions.
• Reports results with 95% confidence intervals and prediction intervals for key outcomes like PFS and ORR.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale statistical modeling.
• The dataset is a 15.4 MB DOCX document, which may require parsing to extract structured data.

Provenance

Source

figshare

Collection Method

Systematic literature search in PubMed, Cochrane Library, Web of Science, and Embase for RCTs published up to January 10, 2026.

Time Range

Trials published up to January 2026.

Freshness

Last updated 2026-04-20 04:11:45; freshness should be verified.

Geography

Global (not specified, inferred from international database search).